Is obstetric antiphospholipid syndrome a primary nonthrombotic, proinflammatory, complement-mediated disorder related to antiphospholipid antibodies?

Obstetrical and Gynecological Survey

Volumn 65, Issue 1, 2010, Pages 39-45

  Alijotas Reig, Jaume ^a,b   Vilardell Tarres, Miquel ^a,b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOLIPID ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; FETUS WASTAGE; HUMAN; PREGNANCY; PREGNANCY OUTCOME; REVIEW; SPONTANEOUS ABORTION;

ABORTION, HABITUAL; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; ARTERIAL OCCLUSIVE DISEASES; FEMALE; HUMANS; INFLAMMATION; PLACENTA DISEASES; PLACENTAL CIRCULATION; PREGNANCY; VENOUS THROMBOEMBOLISM;

EID: 73949110131     PISSN: 00297828     EISSN: 15339866     Source Type: Journal    
DOI: 10.1097/OGX.0b013e3181c97809     Document Type: Review

References (50)

1. Yamaguchi Y, Noriyuki N, Kaburaki J, et al. Excessive exposure to anionic surfaces maintains autoantibody response to B2-glycoprotein I in patients with antiphospholipid syndrome. Blood 2007;110:4312-4318.
2. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 2006; 4:205-306.
3. Hughes GR. Thrombosis, abortion, cerebral disease and lupus anticoagulant. Br Med J 1983;287:1088-1089.
4. Branch DW, Dudley DJ, Mitchell MD, et al. Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BLAB/c mice: a model for autoimmune fetal loss. Am J Obstet Gynecol 1990;163:210-216.
5. Di Simone N, Meroni PL, Del Papa N, et al. Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered B2-glycoprotein 1. Arthritis Rheum 2000;43:140-150.
6. Alijotas-Reig J. Towards the comprehension of heterogeneity of clinical manifestations related to antiphospholipid antibodies. Med Clin (Barc) 2005;125:187-189.
7. Gris JC, Quere I, Sanmarco M, et al. Antiphospholipid and antiprotein syndromes in non-thrombotic non-autoimmune women with unexplained recurrent primary early fetal loss. The Nimes Obstericians and Haematologists Study-NOHA. Thromb Haemost 2000;84:228-236.
8. Asherson RA, Cervera R, Shepshelovich D, et al. Nonthrom-botic manifestations of the antiphospholipid syndrome: away from thrombosis? J Rheumatol 2006;33:1038-1044.
9. Asherson RA, Cervera R, Wells AU. Diffuse alveolar haemorrhage: a non-thrombotic antiphospholipid lung syndrome? Semin Arthritis Rheum 2005;35:138-142.
10. Out HJ, Kooijman CD, Bruinse HW, et al. Histopathological findings in placentae from patients with intra-uterine fetal death and antiphospholipid antibodies. Eur J Obstet Gynecol Reprod Biol 1991;195:211-220.
11. Meroni PL, di Simone N, Testoni C, et al. Antiphospholipid antibodies as cause of pregnancy loss. Lupus 2004;13:649-652.
12. Magid MS, Kaplan C, Sammaritano LR. Placental pathology in systemic lupus erythematosus: a prospective study. Am J Obstet Gynecol 1998;179:226-234.
13. Salmon JE, Girardi G. Antiphospholipid syndrome revisited: a disorder initiated by inflammation. Lupus 2007;16(abstract suppl): 1-2.
14. Meroni PL. Endothelial cell perturbation by anti-phospholipid antibodies in systemic lupus erythematosus. Lupus 2007; 16(abstract suppl):17-18.
15. Holmes CH, Simpson KL. Complement and pregnancy: new insights into the immunobiology of the fetal-maternal relationship. Balliere's Clin Obstet Gynecol 1992;6:439-459.
16. Morgan BP, Holmes CH. Immunology of reproduction: protecting the placenta. Curr Biol 2000;10:R381-R383.
17. Wells M, Bennett J, Bulmer JN, et al. Complement component deposition in uteroplacental arteries in normal human pregnancy. J Reprod Immunol 1987;12:125-135.
18. Holmes CH, Simpson KL, Okada H, et al. Complement regulation proteins at the fetomaternal interface during human placental development distribution of CD59 and decay accelerating (CD55). Eur J Immunol 1992;22:1579-1585.
19. Cunningham DS, Tichenor JR Jr. Decay-accelerating factor protects human trophoblast from complement-mediated attack. Clin Immunol Immunopathol 1995;74:156-161.
20. Burlingham WJ. A lesson in tolerance-maternal instructions to fetal cells. N Engl J Med 2009;360:1355-1357.
21. Alijotas-Reig J. Immunological networks related to recurrent miscarriage: overview. Curr Immunol Rev 2009. In press.
22. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid- induced fetal loss by inhibiting complement activation. Nat Med 2004;10:1222-1226.
23. Girardi G, Berman J, Redecha P. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003;112:1644-1654.
24. Holers VM, Girardi G, Mo L. Complement C3 activation is required for antiphospholipid antibody induced fetal loss. J Exp Med 2002;195:211-220. (Pubitemid 34461265)
25. Pierangeli SS. New targeted therapies for treatment of thrombosis in antiphospholipid syndrome: lessons from in vitro and in vivo studies. Lupus 2007;16(suppl):19-20.
26. Chen R, Ming G, Zhao ML, et al. Mast cells playa key role in neutrophil recruitment in experimental bullous pemphigoid. J Clin Invest 2001;108:1151-1156.
27. Czermak BJ, Sarma V, Bless NM, et al. In vitro and in vivo dependency of chemokine generation on C5a and TNF-a. J Immunol 1999;162:2321-2325.
28. Laudes IJ, Chu JC, Huber-Lang M, et al. Expression and function of C5a receptor in mouse microvascular endothelial cells. J Immunol 2002;169:5962-5970. (Pubitemid 35299387)
29. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996;174:1584-1589.
30. Branch WR, Khamashta MA. Antiphospholipid syndrome: ob-stetricdiagnosis, management, and controversies. Obstet Gy-necol 2003;101:1333-1448.
31. Girardi G, Salmon JB. The role of complement in pregnancy and fetal loss. Autoimmunity 2003;36:19-26.
32. Macfarlane SR, Seatter MJ, Kanke T, et al. Proteinase-activated receptors. Pharmacol Rev 2001;53:245-282.
33. Berman J, Girardi G, Salmon JE. TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol 2005;174:1222-1226.
34. Alijotas-Reig J, Palacio-García C, Vilardell-Tarrés M. Circulating microparticles, lupus anticoagulants and recurrent miscarriages. Eur J Obstet Gynecol Reprod Biol 2009;145:22-26.
35. Monroe DM, Key NS. The tissue factor-FatorVIIa complex: procoagulant activity, regulation, and multitasking. J Thromb Haemost 2007;5:1097-1105.
36. Redecha P, Tilley R, Tencati M, et al. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood 2007;110:2423-2431.
37. Red-Horse K, Zhou Y, Genbacev O, et al. Trophoblast differentiation during embryo implantation and formation of the maternal-fetal interface. J Clin Invest 2004;114:744-754.
38. Lam C, Lim KH, Karumanchi SA. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension 2005;46:1077-1085.
39. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-676.
40. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672-683.
41. Levine RJ, Thadhani R, Quian C, et al. Urinary placental growth factor and risk of preeclampsia. JAMA 2005;293:77-85.
42. Girardi G, Yarilin D, Thurman JM, et al. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med 2006;203:2165-2175.
43. Singhal AB, Kimberly WT, Schaefer PW. Case records of the Massachusetts General Hospital. Case 8-2009. A 36-year-old woman with headache, hypertension, and seizure 2 weeks post partum. N Engl J Med 2009;360:1126-1137.
44. Alijotas-Reig J, Ferrer-Oliveras R, Rodrigo-Anoro MJ, et al. Anti-B2glycoprotein-I and anti-phosphatidylserine antibodies in women with spontaneous pregnancy loss. Fertil Steril. In press.
45. Boffa M-C, Boinot C, de Carolis S, et al. Laboratory criteri of the obstetrical antiphospholipid syndrome (APS). Data from a multicentric propstective European women cohort. Thromb Haemost 2009;102:25-28.
46. Burrow GN, Duffy TP, eds. Medical Complications During Pregnancy. 5th ed. Philapelphia, PA: WB Saunders Company; 1999.
47. Alijotas-Reig J, Izquiedo M, Serra B, et al. Antiphospholipid autoantibodies, complement levels, hypergammaglobuline-mia and spontaneous intrauterine haematomas in pregnant women. Am J Reprod Immunol 2003;49:1-6.
48. 2-glicoprotein-I antibodies markers for recurrent pregnancy loss in lupus anticoagulant/anticardiolipin sero-negative women? Am J Reprod Immunol 2008;60:229-237.
49. Carbone J, Sarmiento E, Rodriguez-Molina J, et al. Hipocomple-mentemia C3 y C4 en el síndrome antifosfolípido obsté trico. Rev Clin Esp 2008;208:168-171.
50. Chu AJ. Tissue factor upregulation drives a thrombosis-inflammation circuit in relation to cardiovascular complications. Cell Biochem Funct 2006;24:173-192.